English to Russian Medical Medical: Pharmaceuticals

Objectives and Endpoints:
To evaluate the efficacy of ruxolitinib 5 mg BID + SoC therapy and ruxolitinib 15 mg BID + SoC therapy compared with placebo + SoC therapy on in-hospital outcomes in participants with COVID-19–associated ARDS who require mechanical ventilation.
At Day 29, the number of ventilator-free days, ICU-free days, oxygen-free days, vasopressor-free days, and hospital-free days summarized by treatment group.